IBRNiShares Neuroscience and Healthcare ETF

Grow my money3y track recordRanked #2,298 of 2,960 in this goal

Seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from neuroscience.

By iShares · Launched 2022

Annual Cost

0.47%

#2,305 of 5,562 · average

Fund Size

$5M

#5,034 of 5,562 · small

Return (1Y)Goal

+63.6%

Track Record

3 years

#2,761 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$16,307+63.1%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Medical Devices

Index tracked

NYSE FactSet Global Neuro Biopharma and MedTech Index

What it actually holds

By weight

Concentration

Top 10 holdings = 50.5% of fundmoderately concentrated

BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares

13.3%

Praxis Precision Medicines Inc

5.0%

AXSOME THERAPEUTICS, INC.

4.9%

ALKERMES PUBLIC LIMITED COMPANY

4.6%

BIOGEN INC.

3.9%

Scholar Rock Holding Corp

3.9%

PTC THERAPEUTICS, INC.

3.9%

Denali Therapeutics Inc

3.7%

argenx SE

3.7%

ACADIA PHARMACEUTICALS INC.

3.6%

Asset allocation

Stocks

99.8%

Cash

0.2%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

25.5%High

Year-on-year price swings

Max drawdown

-35.4%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.44Below average

Sortino (3Y)

0.64Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from neuroscience.
Strategy: Tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, which measures equity securities of companies involved in neurology biopharmaceuticals or neurological devices. The Fund invests primarily in component securities and aims to keep portfolio turnover low compared to actively managed funds.
Inception date: August 24, 2022
Fund family: iShares